Puma Biotechnology Inc (PBYI)

NMS · Healthcare · Biotechnology

$7.33 +1.38%

Closing price as of 2026-06-12 · Source: TEK2day Finance

1-Year Price History +105.9% over period

Key Metrics

Market Cap

$373.1M

P/S (TTM)

1.6x

P/E (TTM)

15.3x

Exchange

NMS

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Quarterly Financials

Metric	2025-06-30	2025-09-30	2025-12-31	2026-03-31
Revenue	52.4M	54.5M	75.5M	44.8M
Gross Profit	40.1M	42.3M	52.3M	34.4M
Operating Income	6.6M	9.6M	17.1M	-3.8M
Net Income	5.9M	8.8M	13.4M	-3.8M
Diluted EPS	$0.12	$0.17	$0.26	$-0.07

Annual Financials

Metric	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Revenue	228.0M	235.6M	230.5M	228.4M
Gross Profit	172.9M	173.0M	166.1M	170.2M
Operating Income	30.7M	32.6M	31.0M	37.3M
Net Income	2K	21.6M	30.3M	31.1M
Diluted EPS	$0.00	$0.45	$0.62	$0.61